CVS Furnishes earnings results (Ex. 99.1)
Summary
CVS Health Corporation announced its third quarter 2025 results and updated its full-year 2025 guidance on October 29, 2025, via Exhibit 99.1. The company reported record total revenues of $102.9 billion, up 7.8% compared to the prior year. GAAP diluted loss per share was $3.13, inclusive of a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit, while Adjusted EPS reached $1.60. * Updated full-year GAAP diluted EPS guidance to $(0.34) to $(0.24). * Raised full-year Adjusted EPS guidance to $6.55 to $6.65. * Updated cash flow from operations guidance to a range of $7.5 billion to $8.0 billion. * Caremark closed a strong selling season with contract wins totaling nearly $6.0 billion.
Why It Matters
Investors should note the record high revenues and the updated full-year guidance, particularly the raised Adjusted EPS guidance, which signals improved operational performance. The significant $5.7 billion goodwill impairment charge, leading to a GAAP diluted loss per share, is also a critical factor for assessing the company's asset valuation and profitability.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how CVS traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View CVS Charts on TradingViewAffiliate link
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000064803
- Filing Date
- Wednesday, October 29, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- neutral